JPMorgan Gives Hims & Hers a $35 Bullish Rating – Full GLP-1 Lineup Just Got Even Stronger
JPMorgan backs Hims & Hers Health as a strong buy, boosted by GLP-1 drugs and big deals with Novo Nordisk and Eli Lilly.
/ 1659 items
#XY↓
Cannabis Stocks Drop After Early Surge on Limited US Marijuana Rescheduling Move
Cannabis stocks fell after hype faded: US reform helps medical marijuana only, not full market, so investors took profits.
Regeneron Strikes Deal with Trump: Free Gene Therapy for Hearing Loss + Lower Drug Prices for Americans
Regeneron will cut U.S. drug prices, offer free gene therapy for hearing loss, and align costs with other countries under a Trump deal.
Grace Therapeutics Gets FDA Feedback on GTx-104: No New Clinical Trials Needed, Resubmission Planned
FDA flagged fixable issues for GTx-104, not rejection. No new trials needed. IV drug may improve brain bleed ICU treatment.
OpenAI’s Free ChatGPT for Doctors Triggers Doximity Stock Slide
OpenAI launched ChatGPT for doctors to help with notes and research. It’s free in the US, boosts AI use, and Doximity stock fell.
IKS Health Acquires TruBridge to Boost Rural Healthcare Access
IKS Health is buying TruBridge to improve rural US healthcare using AI. Deal helps 2000 hospitals, closes 2026.